This study is testing a new oral medication called HLD-0915 in different forms (hard capsule, soft capsule, tablet) for men with metastatic prostate cancer (cancer that has spread to other parts of the body). The main goals are to find a safe dose of HLD-0915, understand its side effects, and see how well the different forms of the drug are absorbed by the body. Later parts of the study will also look at how effective HLD-0915 is against the cancer. You may be able to join if you are a man at least 18 years old with confirmed prostate cancer that has spread, and you have good blood, kidney, and liver function. The current status of the study is unclear, and it plans to enroll about 190 participants.

Study design

This is a Phase 1/2 study, meaning it first looks at safety and dosage, then expands to evaluate effectiveness. It is an open-label study, so both you and your doctors will know which treatment you are receiving.

What's involved

The study will measure the frequency and severity of side effects, and changes in your heart (ECG), lab tests, and clinical status over 21 to 22 days.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for safety and drug absorption are measured at 21 to 22 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.